Vaccine News and Research

Latest Vaccine News and Research

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen.

23 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

A team of scientists from the United States has recently compared the immune response elicited by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Their findings reveal that, unlike vaccination, natural SARS-CoV-2 infection is associated with a robust interferon response together with an induction of cytotoxic gene expression in peripheral blood lymphocytes. The study is currently available on the medRxiv* preprint server.

22 Apr 2021

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Researchers in the United States have shown that the antibody response induced by the Moderna mRNA-1273 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a correlate of immune protection against coronavirus disease 2019 (COVID-19) in non-human primates.

22 Apr 2021

Slow COVID-19 vaccine rollout in Tokyo could mean no Olympic and Paralympic Games

Researchers in Japan have warned that Tokyo's Olympic and Paralympic Games, which is set to start in July 2021, may need canceling if the rollout of vaccination to protect against coronavirus disease 2019 (COVID-19) continues at the slow pace it is now.

22 Apr 2021

Changing the treatment paradigm for ‘cold’ tumors

Not all cancerous tumors are created equal. Some tumors, known as "hot" tumors, show signs of inflammation, which means they are infiltrated with T cells working to fight the cancer. Those tumors are easier to treat, as immunotherapy drugs can then amp up the immune response.

22 Apr 2021

Study finds higher mortality rate among pregnant women affected by COVID-19

In a worldwide study of 2,100 pregnant women, those who contracted COVID-19 during pregnancy were 20 times more likely to die than those who did not contract the virus.

22 Apr 2021

KHN’s ‘What the Health?’: Picking up the pace of undoing Trump policies

The Biden administration is speeding up the pace of efforts to undo Trump administration health policies.

22 Apr 2021

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.

22 Apr 2021

Pre-Clinical Vaccine Adjuvant and Therapeutics Manufacturing

Analytik reports how its Microfluidizer® processors are enabling researchers develop a range of therapeutic formulations including vaccine adjuvants, liposomes and lipid nanoparticles.

From Analytik Ltd 22 Apr 2021

California and Texas took different routes to vaccination. Who’s ahead?

California and Texas, the country's two most populous states, have taken radically different approaches to the pandemic and the vaccination campaign to end it.

22 Apr 2021

Cleaning frequency key to limiting SARS-CoV-2 spread at theme parks

A new preprint research paper provides some insights into how this may be done using computational modeling. The study, which appeared on the medRxiv server, deals with the mitigation strategies that must be implemented in order to contain the virus.

22 Apr 2021

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.

21 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world.

21 Apr 2021

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Drawing on epidemiological field studies and the FrenchCOVID hospital cohort coordinated by Inserm, teams from the Institut Pasteur, the CNRS and the Vaccine Research Institute (VRI, Inserm/University Paris-Est Créteil) studied the antibodies induced in individuals with asymptomatic or symptomatic SARS-CoV-2 infection.

21 Apr 2021

Immune escape by SARS-CoV-2 mutations acquired in mink

A new study, published in Cell Reports, suggests that SARS-CoV-2 may have acquired such immune evasion mutations during its transmission in farmed mink.

21 Apr 2021

FDA takes steps to ensure that COVID-19 vaccines meet high standards for quality, safety and effectiveness

The U.S. Food and Drug Administration takes its responsibility to ensure medical product quality, safety and effectiveness very seriously.

21 Apr 2021

Censorship or misinformation? Desantis and YouTube spar over Covid roundtable takedown.

In early April, YouTube took down a video featuring Florida Gov. Ron DeSantis and a group of controversial scientists at a March 18 coronavirus roundtable. The online video platform, owned by Google, cited as its rationale that the video contained false statements about the efficacy of children's mask-wearing.

21 Apr 2021

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Vaccine News and Research

Latest Vaccine News and Research

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

Celastrol shows potential anti-SARS-CoV-2 activity

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Slow COVID-19 vaccine rollout in Tokyo could mean no Olympic and Paralympic Games

Changing the treatment paradigm for ‘cold’ tumors

Study finds higher mortality rate among pregnant women affected by COVID-19

KHN’s ‘What the Health?’: Picking up the pace of undoing Trump policies

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Pre-Clinical Vaccine Adjuvant and Therapeutics Manufacturing

California and Texas took different routes to vaccination. Who’s ahead?

Cleaning frequency key to limiting SARS-CoV-2 spread at theme parks

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Immune escape by SARS-CoV-2 mutations acquired in mink

FDA takes steps to ensure that COVID-19 vaccines meet high standards for quality, safety and effectiveness

Censorship or misinformation? Desantis and YouTube spar over Covid roundtable takedown.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in